Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth
- Ferragut, Fatima Eneida del Valle
- Cagnoni, Alejandro
- Colombo, Lucas Luis
- Sánchez Terrero, Clara
- Wolfenstein Todel, Carlota
- Troncoso, María Fernanda
- Vanzulli, Silvia
- Rabinovich, Gabriel Adrián
- Mariño, Karina Valeria
- Elola, Maria Teresa
DOIAbstract
Galectin-8 (Gal-8), a ‘tandem-repeat’-type galectin, has been described as a modulator of cellular functions including adhesion, spreading, growth arrest, apoptosis, pathogen recognition, autophagy, and immunomodulation. We have previously shown that activated leukocyte cell adhesion molecule (ALCAM), also known as CD166, serves as a receptor for endogenous Gal-8. ALCAM is a member of the immunoglobulin superfamily involved in cell-cell adhesion through homophilic (ALCAM-ALCAM) and heterophilic (i.e. ALCAM-CD6) interactions in different tissues. Here we investigated the physiologic relevance of ALCAM-Gal-8 association and glycosylation-dependent mechanisms governing these interactions. We found that silencing of ALCAM in MDA-MB-231 triple n...
Add to ORKG